The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.
Individuals with heterozygous Familial Hypercholesterolemia.
Myocardial infarction or stroke within the last 6 months
unstable angina, symptoms of angina within the last 3 months
NYHA class III or IV heart failure or LVEF < 30%
poorly controlled hypertension: SBP > 180 mm Hg or DBP > 110 mm Hg,
Vanderbilt University Medical Center
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator